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Chromosome position 9p21 encodes three-tumor suppressors p16INK4a, p14ARF, and 
p15INK4b and the long non-coding RNA ANRIL (antisense non-coding RNA in the INK4 
locus). The rs11515 single-nucleotide polymorphism in the p16INK4a/p14ARF 3′-untrans-
lated region is associated with glioblastoma, melanoma, and other cancers. This study 
investigated the frequency and effect of rs11515 genotypes in breast cancer. Genomic 
DNA samples from 400 women (200 with and 200 without a diagnosis of breast cancer) 
were genotyped for the rs11515 major (C) and minor (G) alleles. The rs11515 polymor-
phism was also investigated in 108 heart tissues to test for tissue-specific effects. Four 
9p21 transcripts, p16INK4a, p14ARF, p15INK4b, and ANRIL were measured in breast tumors 
and myocardium using quantitative PCR. Heterozygotes (CG genotype) were more fre-
quent in women with breast cancer compared to the control population (P = 0.0039). In 
those with breast cancer, the CG genotype was associated with an older age (P = 0.016) 
and increased lymph node involvement (P =  0.007) compared to homozygotes for 
the major allele (CC genotype). In breast tumors, the CG genotype had higher ANRIL 
(P = 0.031) and lower p16INK4a (P = 0.006) expression compared to the CC genotype. 
The CG genotype was not associated with altered 9p21 transcripts in heart tissue. In 
breast cancer, the rs11515 CG genotype is more frequent and associated with a more 
aggressive tumor that could be due to increased ANRIL and reduced p16INK4a expression. 
The absence of association between rs11515 genotypes and 9p21 transcripts in heart 
tissue suggests this polymorphism has tissue- or disease-specific functions.
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inTrODUcTiOn
Single-nucleotide polymorphisms (SNPs) within the 9p21 locus 
are associated with coronary artery disease (1–3) and multiple 
cancer types (4–7), suggesting this region is significant toward 
disease susceptibility. Three proteins encoded at 9p21 are well-
defined tumor suppressors. The p16INK4a and p15INK4b proteins limit 
cell proliferation by inhibiting cyclin-dependent kinases, and the 
third tumor suppressor (p14ARF) prevents the degradation of p53 
[reviewed in Ref. (8, 9)]. Different open-reading frames of the 
cyclin dependent kinase 2A (CDKN2A) gene encode p16INK4a and 
p14ARF, while p15INK4b is encoded by a separate gene (CDKN2B).
The rs11515 polymorphism in the CDKN2A 3′-untranslated 
region (UTR) consists of a major (C) and minor (G) allele at 
cDNA nucleotide 500 (numbered from the p16INK4a initiation 
codon). It has been associated with melanoma, sporadic colorec-
tal, skin, bladder, and cervical cancers (10–17). In glioblastoma, 
the rs11515 G allele was associated with a worse prognosis and 
older age (17). This polymorphism is 5′ to the long non-coding 
RNA ANRIL (antisense non-coding RNA in the INK4 locus, also 
known as CDKN2B-AS1) (18). Increased ANRIL is associated 
with increased proliferation, metabolic activity, inflammation, 
and attenuation of apoptosis (19–22). Silencing of ANRIL pre-
vented fibroblast and smooth muscle cell proliferation (19, 20) 
as ANRIL is increased as part of a bacterial response ANRIL may 
function as part of an inflammatory response (22). This and other 
evidence, including the findings of increased ANRIL in prostate 
cancer, leukemia, glioma, and breast cancer suggest ANRIL, may 
promote tumorigenesis (19, 23–26).
Given the association of the CDKN2A rs11515 and the func-
tions of proteins encoded at 9p21 in cancer, the current study 
investigated rs11515 genotypes in breast cancer.
MaTerials anD MeThODs
Patients
For the breast cancer analyses, the patient cohort consisted of 200 
women diagnosed with primary breast cancer who underwent 
surgery at Christchurch hospital, New Zealand. The mean age 
for the breast cancer cohort was 59.7 years (95% CI 57.6–61.8). 
Ethnicity data were available for 152 women (87% identified as 
European, 3% Maori, 3% Maori and European, and 7% identified 
with other ethnic groups). The control cohort consisted of 200 
healthy women from the New Zealand population. The mean age 
of the control cohort was 56 years (95 CI percentile 54–58.5 years). 
Ethnicity data were available for all in the control cohort. Eighty-
five percent identified as European, 3% Maori, 5% Maori and 
European, and 7% identified with other ethnic groups. There was 
no significant difference in age between the patient and control 
cohorts. Frozen breast tumors were available for 25 women (12 
women with the CG and 13 with the CC genotype). Tumor tissue 
was limited for four individuals with the CG genotype; therefore, 
some analyses were performed on 8 instead of 12 tumors. The 
breast tumors were selected so that four variables were matched 
between those with the CG and CC genotypes (tumor grade, 
presence of lymph/vascular invasion, ≥2 lymph nodes affected, 
and an estrogen-receptor positive tumor). All breast tumors 
were from women who did not have previous treatment with 
radiotherapy or chemotherapy before surgery.
For the analysis of heart tissue, tissue from the left ventricular 
free wall of the myocardium of organ donors (n =  108) was 
collected by the Cleveland Clinic Kaufman Center for the Heart 
Failure Human Heart Tissue Bank between 1993 and 2006, as 
previously described (27).
For the breast tumor study, ethical approval was obtained 
in New Zealand, and all women gave written informed con-
sent for inclusion in the study (Ethics Committee Approvals 
02.06.98/5.11.09 and LRS/10/09/035). Standard procedures were 
followed, which included culturally appropriate tissue handling 
and disposal protocols (28). For the heart tissue study, ethical 
approval was obtained from the Cleveland Clinic Internal Review 
Board (IRB 2378), and the study adhered to the principles out-
lined in the Declaration of Helsinki. All procedures followed were 
in accordance with institutional guidelines and all families and/or 
patients provided informed consent.
rs11515 genotyping
The C and G rs11515 alleles were genotyped in the breast 
tumor and control cohorts using a PCR and restriction enzyme 
digestion method. Genomic DNA was extracted from blood 
leukocytes using the Dneasy Blood & Tissue Kit (Qiagen, Veno, 
Netherlands) according to the manufacturer’s instructions. 
A 319  bp region was amplified using the following primers: 
forward, 5′-TGCCACACATCTTTGACCTC-3′; reverse, 
5′-GCAGAAGCGGTGTTTTTCTT-3′. Following conformation 
of the correct PCR product, amplified DNA was digested with 
the MspI restriction enzyme. Restriction enzyme-digested PCR 
products were separated by agarose gel electrophoresis to iden-
tify the rs11515 genotype (C allele, digested band; and G allele, 
undigested band). DNA sequencing was performed on 20 PCR 
products to confirm genotypes as described previously (17).
The C500 and G500 rs11515 alleles were genotyped in heart 
tissue using a Taqman SNP assay (C_12096259_10, Applied 
Biosystems, Foster City, CA, USA). Genomic DNA was extracted 
from frozen tissue as previously described (27) and from samples 
genotyped in duplicate using the Lightcycler 480 platform and 
Lightcycler 480 software, version 1.5.0 (Roche, Indianapolis, IN, 
USA). Reactions were optimized for 5 μL volumes with 0.5× the 
recommended probe concentration.
rs3088440 genotyping
For the breast tumor study, rs3088440 alleles were genotyped 
in the patient and control cohorts using a PCR and restric-
tion enzyme digestion method. A 180  bp region was ampli-
fied from blood leukocyte genomic DNA using the following 
primers: forward, 5′-TAGATCATCAGTCACCGAAGG-3′; 
reverse, 5′-CATTTACGGTAGTGGGGGAAG-3′. Following 
conformation of the correct PCR product, amplified DNA 
was digested with the HaeIII restriction enzyme. Restriction 
enzyme-digested PCR products were separated by agarose gel 
electrophoresis to identify the major allele (digested band) and 
the minor allele (undigested band). DNA sequencing was per-
formed on 20 PCR products to confirm genotypes as described 
previously (17).
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CDKN2A gene Dosage
The gene dosage of CDKN2A, exon 1α (p16INK4a), and exon 1β 
(p14ARF) was estimated in 13 breast tumors with the CC and 12 
tumors with the CG rs11515 genotype using a multiplex PCR 
assay, as previously described (29). Tumor DNA was extracted 
using the Qiagen Dneasy Blood & Tissue Kit according to the 
manufacturer’s instructions (Qiagen, Limburg, The Netherlands). 
The intensity of the CDKN2A and β-globin PCR products was 
compared using Bio-Rad Quantity One software (Bio-Rad 
Laboratories, CA, USA) and Syngene GeneTools image software 
(Syngene, Cambridge, UK) as previously described (17).
Quantitative real-Time Pcr
For the breast tumor study, quantitative real-time PCR (RT-qPCR) 
was performed for CDKN2A/p16INK4a, CDKN2A/p14ARF, 
CDKN2B, and ANRIL. RNA was extracted from frozen tissue 
using the Ambion Purelink RNA Mini Kit (Life Technologies, 
Carlsbad, CA, USA) and tissue was homogenized (gentleMACS 
dissociator gentleMACs, Miltenyi Biotec, GmbH, Germany) 
according to the manufacturers’ instructions. Quantitative 
RT-qPCR was performed using Taqman Gene Expression assays 
with inventoried probes (Applied Biosystems, ThermoFisher 
Scientific, Waltham, MA, USA) for CDKN2A/p16INK4a (assay id: 
Hs02902543_mH), CDKN2A/p14ARF (assay id: Hs99999189_m1), 
CDKN2B (assay id: Hs00793225_m1) and ANRIL (assay id: 
Hs01390879_m1). Reactions were performed in duplicate on a 
Lightcycler 480 platform (Roche, Basel, Switzerland) and ana-
lyzed with Lightcycler 480 software, version 1.5.0 (Roche, Basel, 
Switzerland). Expression levels were converted to relative quanti-
ties and normalized to tumor protein, translationally controlled 
1 (TPT1, assay id Hs02621289_g1) and eukaryotic elongation 
factor 1A1 (EEF1A1, assay id Hs00265885_g1), two reference 
genes previously validated for normalization of RT-qPCR data in 
breast and cancer cell types (30, 31).
For the study of heart donors, expression data for CDKN2A/
p16INK4a and CDKN2A/p14ARF was obtained in the current study, 
and that for CDKN2B and ANRIL generated as part of a previous 
study (27) and included in the current analysis. RT-qPCR was 
performed using Taqman Gene Expression assays for CDKN2A/
p16INK4a (assay id: Hs02902543_mH), CDKN2A/p14ARF (assay 
id: Hs99999189_m1), CDKN2B (assay id: Hs00793225_m1), 
and ANRIL (assay id: Hs01390879_m1) as described 
above. Expression levels were normalized to TPT1 (assay id 
Hs02621289_g1), EEF1A1 (assay id Hs00265885_g1) and signal 
recognition particle 14 kDa (SRP14, assay id Hs03055045_g1), 
three reference genes previously validated for use in human 
myocardium (32).
statistical analyses
The genotype frequencies were compared between cases 
and controls using the Chi-square test and SHEsis software 
(33). For breast tumors and heart samples, clinicopathologic 
measures were compared between genotypes using Chi-square 
and one-way ANOVA followed by pairwise comparisons tests. 
All gene expression levels displayed skewed distributions and 
were loge-transformed prior to analysis. Associations between 
gene expression and rs11515 genotypes were performed with 
analysis of variance (genotypic model), with adjustment for age, 
as appropriate. Correlations in expression levels between genes 
were tested with Pearson correlation. Statistical analyses were 
performed with SPSS version 22 software and P < 0.05 was taken 
as a significant difference.
resUlTs
The rs11515 Minor allele Was More 
Frequent in Women with Breast cancer
The rs11515 alleles were genotyped in woman with breast 
cancer and healthy women. In women with breast cancer, 
61% (n  =  121) were homozygote for the major allele (CC, 
genotype), 38% (n =  76) were heterozygote (CG, genotype), 
and 1.5% (n = 3) were homozygote for the minor allele (GG, 
genotype). The genotypes of 20 samples were confirmed using 
DNA sequencing (7 typed as CC, 10 typed as CG, and 3 typed as 
GG). In the control population, 76% (n = 152) had the CC, 23% 
had the CG (n = 46), and 1% of women had the GG genotype. 
The genotype frequencies in controls were in Hardy–Weinberg 
equilibrium (P = 0.47). The CG genotype was more frequent in 
women with breast cancer compared to the control population 
(P = 0.0039).
Clinicopathologic variables (patient age at presentation, 
tumor size, the number of nodes involved, venous and lymphatic 
invasion, estrogen receptor, progesterone receptor, and human 
epidermal growth factor 2 receptor statuses) among rs11515 
genotypes are shown in Table  1 and were compared between 
genotypes in the breast cancer cohort. The mean age for those 
with the CG allele was higher (63.3 years, 95% CI 60–66.5 years) 
compared to those with the CC genotype (58.2  years, 95% CI, 
55.6–60.7 years, P = 0.016). Few women had the GG genotype, 
but all three women with this genotype were young (aged 23, 33, 
and 35 years).
The CG genotype was associated with a more aggressive 
tumor with greater lymph node involvement. Forty-five percent 
of women with the CG genotype had two or more nodes with 
malignant cells, and 38% had no nodal involvement. In those with 
the CC genotype, 21% had two or more nodes with malignant 
cells and 60% had no nodal involvement (P = 0.007). The tumor 
size and hormone receptor statuses did not differ between the 
rs11515 genotypes.
The rs11515 polymorphism is located in close proximity to 
another polymorphism associated with breast cancer (rs3088440) 
(34). To determine if rs3088440 genotypes were increased in the 
breast cancer cohort, the rs3088440 polymorphism was geno-
typed. In the breast cancer, cohort 78% (n = 155) were homozy-
gote for the major allele, 21% were heterozygote (n = 42), and 
1.5% (n = 3) were homozygote for the minor allele. In the control 
cohort, 82% (n = 164) were homozygote for the major allele, 17% 
were heterozygote (n = 34), and 1% (n = 2) were homozygote for 
the minor allele. The rs3088440 genotype was not significantly 
different in women with breast cancer compared to the control 
population. Nine individuals were heterozygote for both the 
rs11515 and rs3088440 SNPs.
TaBle 1 | characteristics of the 200 women with breast cancer relative to their rs11515 genotype.
characteristic rs11515 genotype significance
cc (n = 121) cg (n = 76) gg (n = 3)
Age at surgery years 58.2 (55.6–60.7) 63.3 (60–66.5) 30.3 (14.1–46.5) 0.0001
Tumor grade
1 17 (15.2%) 9 (11.8%) 3 (100%) ns
2 42 (37.5%) 34 (44.7%)
3 53 (47.3%) 33 (43.4%)
Not known 9
Lymph/vascular invasion present 37 (30.6%) 38 (50%) 1 (33.3%) ns
Tumor size (mm) 24.2 (21–27.3) 26.4 (22.5–30.4)  38.3 (18.8–57.9) ns
Metastases to lymph nodes
None 73 (60.3%) 29 (38.2%) 1 (33.3%) 0.007
1 node 23 (19%) 13 (17.1%) 1 (33.3%)
≥2 nodes 25 (20.7%) 34 (44.7%) 1 (33.3%)
Estrogen Receptor
Negative 34 (30.4%) 20 (26.3%) 1 (33.3%) ns
Positive 72 (64.3%) 52 (68.4%) 2 (66.7%)
Equivocal 6 (5.4%) 4 (5.3%)
Data not known 10 0
Progesterone receptor
Negative 47 (42%) 31 (40.8%) 1 (33.3%) ns
Positive 56 (50%) 37 (48.7%) 2 (66.7%)
Equivocal 9 (8%) 8 (10.5%)
Data not known 9 0
HER2 receptor
Negative 30 (58.8%) 24 (75%) 2 (66.7%) ns
Positive 16 (31.4%) 8 (25%) 1 (33.3%)
Equivocal 5 (9.8%) 0
Data not known 69 44 
Results are the mean (95% confidence intervals), or the n value (percent positive).
P values represent the comparison between three genotypes.
ns, not significant.
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The cg genotype Was associated 
With increased ANRIL expression in 
Breast Tumors
In glioblastoma patients, the CG genotype was associated with 
increased loss of p16INK4a and p14ARF due to gene deletions at 9p21 
(17). To determine if this was the case in breast cancer, DNA was 
isolated from 25 breast tumors (12 from women with the CG 
genotype and 13 with the CC genotype), and multiplex PCR used 
to estimate the gene dosage of CDKN2A exon 1a (p16INK4a) and 
exon 1b (p14ARF) relative to an internal beta-globin gene fragment 
(29). All breast tumors had retained exon 1a and exon 1b (data 
not shown), suggesting the CG genotype was not associated with 
loss of p16INK4a and p14ARF gene dosage.
Polymorphisms in CDKN2A/2B/ANRIL may regulate gene 
expression within the cluster. To test this hypothesis, we inves-
tigated associations between rs11515 genotypes and expression 
of CDKN2A (transcripts, p16INK4a and p14ARF), and CDKN2B in 
25 breast tumors (12 from women with the CG genotype and 13 
with the CC genotype). Due to the limited availability of tumor 
tissue for those with the CG genotype, ANRIL was measured in 
21 breast tumors (8 from women with the CG genotype and 13 
with the CC genotype).
Compared to the CC genotype, the CG genotype was asso-
ciated with lower expression of CDKN2A/p16INK4a [2.6-fold, 
P = 0.006 (adjusted for age), Figure 1A] and higher expression 
of ANRIL (2.3-fold, P = 0.031, Figure 1B). There was no differ-
ence in expression of CDKN2A/p14ARF (P = 0.513, Figure 1C) or 
CDKN2B [P = 0.404 (adjusted for age), Figure 1D] between the 
genotype groups.
Because ANRIL may regulate the expression of CDKN2A/
p16INK4a and because expression levels of both of these genes 
were altered in association with the rs11515 genotype, we inves-
tigated the relationship between rs11515 genotype, ANRIL, and 
CDKN2A/p16INK4a expression further, using analysis of covari-
ance. We identified a significant interaction between rs11515 
and ANRIL on expression of CDKN2A/p16INK4a: in patients with 
a CG genotype levels of ANRIL were strongly negatively cor-
related with levels of CDKN2A/p16INK4a (Pearson Correlation 
Coefficient  =  −0.941, P  <  0.001, Figure  2A), whereas in 
CC patients there was no correlation between ANRIL and 
CDKN2A/p16INK4a (Pearson Correlation Coefficient  =  0.079, 
P  =  0.798, Figure  2B). The interaction between rs11515 
and ANRIL on CDKN2A/p16INK4a expression remained 
significant after adjustment for age (adjusted P  =  0.014) 
indicating that the relationship between rs11515, ANRIL, 
FigUre 2 | scatterplots illustrating the interaction between rs11515 genotypes and ANRIL on CDKN2A/p16 INK4a gene expression in breast tumor 
samples. (a) In tumors with a CG genotype, ANRIL and CDKN2A/p16INK4a levels were strongly negatively correlated. (B) In contrast, in tumors with a CC genotype, 
ANRIL and CDKN2A/p16INK4a levels were not correlated. PCC = Pearson correlation coefficient.
FigUre 1 | Boxplots illustrating associations between gene expression and rs11515 genotypes in breast tumor samples. Compared with tumors with a 
CC genotype, expression of CDKN2A/p16INK4a was lower (a) and expression of ANRIL was higher (B) in tumors with a CG genotype. There were no associations 
between rs11515 genotype and expression levels of CDKN2A/p14ARF (c) or CDKN2B/p15INK4b (D) between CG and CC genotypes in breast tumor tissue.
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and CDKN2A/p16INK4a was not influenced by this potential 
confounding factor.
To test whether the association between rs11515 genotypes and 
altered expression of the CDKN2A/2B/ANRIL cluster occurred 
in other tissues, we investigated rs11515 genotypes in 108 heart 
donors. The rs11515 genotype frequencies in heart donors were 
CC 67.6% (n = 73), CG 28.7% (n = 31), and GG 3.7% (n = 4) 
and were in Hardy–Weinberg equilibrium (P =  0.755). There 
were no associations between rs11515 genotypes and age and 
left ventricular ejection fraction and cause of death (Table  2). 
There were also no associations between rs11515 genotype and 
expression of CDKN2A/p16INK4a (P =  0.940), CDKN2A/p14ARF 
(P =  0.641), CDKN2B (P =  0.116), or ANRIL (P =  0.701) in 
myocardium. No interaction between the rs11515 genotype and 
TaBle 2 | characteristics of the 108 heart donors relative to their rs11515 
genotype.
characteristic rs11515 genotype significance 
cc 
(n = 73)
cg 
(n = 31)
gg  
(n = 4)
Age (years) 47.9 
(45.0–50.9)
46.5 
(41.9–51.0) 
57.0 
(44.5–69.5)
0.294
Gender
Male 41 (56.2%) 12 (40.0%) 2 (50.0%) 0.328
Female 32 (43.8%) 18 (60.0%) 2 (50.0%)
Left ventricular 
ejection fraction (%)
53.0 
(48.1–57.9)
49.4 
(41.6–57.2)
54.2 
(36.1–72.2)
0.722
Cause of death
Cerebral vascular 
accident
52 (71.2%) 22 (73.3%) 4 (100.0%) 0.986
Gun shot wound 7 (9.6%) 3 (10.0%) 0 (0.0%)
Motor vehicle accident 7 (9.6%) 2 (6.7%) 0 (0.0%)
Head trauma 5 (6.8%) 2 (6.7%) 0 (0.0%)
Anoxia 2 (2.7%) 1 (3.3%) 0 (0.0%)
Results are the mean (95% confidence intervals) or the n value (percent positive).  
P values represent the comparison between three genotypes.
FigUre 3 | scatterplots illustrating the interaction between rs11515 genotypes and ANRIL on CDKN2A/p16 INK4a gene expression in heart tissue. The 
CG genotype (a) and the CC (B) genotype in heart tissue showed was no correlation between ANRIL and CDKN2A/p16INK4a expression levels.
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ANRIL on CDKN2A/p16INK4a levels (P =  0.124) was identified. 
In heart donors, there was no significant interaction between 
rs11515 genotypes and ANRIL on expression of CDKN2A/p16INKa, 
Figure 3. All myocardial gene expression analyses were adjusted 
for age and gender. These results suggest the effect of rs11515 
genotypes on 9p21 gene expression is tissue and or disease related.
DiscUssiOn
The current study adds breast cancer to a growing list of malig-
nancies associated with the rs11515 minor allele (10–17). The 
CG genotype was more frequent in those with breast cancer, 
associated with an older age and a more invasive tumor, and 
found with a negative correlation between ANRIL and p16INK4a. 
These data suggest the CG genotype is associated with a more 
aggressive tumor.
Reduced p16INK4a tumor suppressor function in combina-
tion with increased ANRIL offers an explanation for increased 
cancer susceptibility with the rs11515 minor allele. An associa-
tion between the CG genotype and lower expression of p16INK4a 
is consistent with previous studies. In melanoma and colorectal 
carcinoma, the G allele was associated with loss of p16INK4a and 
p14ARF expression, and in glioblastoma, CG genotype was associ-
ated with reduced p16INK4a and p14ARF gene dosage (13, 14, 17). 
The observation that ANRIL levels were higher and negatively 
correlated with p16INK4a in patients with the CG genotype, sug-
gests ANRIL may be upregulated and acting to repress p16INK4a 
expression. There is evidence to suggest ANRIL affects expression 
of 9p21 transcripts by acting as a scaffold to guide chromatin-
remodeling proteins toward 9p21 (19, 21, 35–37). ANRIL may 
promote the formation of heterochromatin facilitating reduced 
expression of p16INK4a expression. A specific example is the bind-
ing of ANRIL to polycomb repressive complexes 1 and 2 (PRC1 
and PRC2) that is thought to direct epigenetic regulation and 
reduced p16INK4a and p15INK4b (19, 35).
Other data suggest increased ANRIL would be associated 
with increased rather than decreased expression at 9p21 in breast 
cancer. Using TCGA expression data for invasive breast cancer, 
ANRIL and CDKN2A (p14ARF and p16INK4a combined) were 
positively correlated (Pearson correlation 0.588, Figure 4A) (38, 
39), with a marginal positive correlation between ANRIL and 
p15INK4b (Pearson Correlation 0.39, Figure  4B). An analysis of 
12 breast tumors by Pasmant et al. (18) found increased ANRIL 
correlated with increased p14ARF, p16INK4a, and p15INK4b (18). 
The available TCGA data are not divided based on the rs11515 
genotype. Considering most women will be homozygote for the 
major rs11515 allele, the inconsistency between the TCGA data 
with that from the current study raises the possibility that the 
relationship between ANRIL and p16INK4a may be influenced by 
the rs11515 genotype, with an inverse relationship for those with 
the CG but not the CC genotype.
Although we argue that the CG genotype is correlated with 
increased risk toward breast cancer due to increased nodal involve-
ment, increased ANRIL, and reduced p16INK4a expression, it could 
be argued that the CC genotype is the risk genotype. Patients 
with the CC genotype were younger. In another study, increased 
rather than decreased expression of p16INK4a was associated with 
a higher breast tumor grade and increased proliferative capacity 
FigUre 4 | Dot-plots from Tcga data for invasive breast cancer to 
illustrate correlations between 9p21 transcripts. ANRIL (CDKN2B-AS1) 
and CDKN2A (p16INK4a and p14ARF) (a) and CDKN2B (p15INK4b) (B) (38, 39).
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(40). It could be that the CG genotype protects against tumors 
initially, but with age tumor surveillance may be compromised 
leading to a more aggressive tumor. The current study did not 
investigate ANRIL expression in normal associated breast tissue, 
so we did not determine whether it is the CG or CC genotype that 
is aberrant for ANRIL expression in breast tumors. Those with the 
GG genotype were young and this supports the G rs11515 allele 
being the risk allele for breast cancer. However, few had the GG 
genotype and breast tissue from GG homozygotes was not avail-
able to determine if ANRIL expression is greatest in these women.
The association between the CG genotype and ANRIL did not 
occur in heart tissue, suggesting the effect of rs11515 alleles is tis-
sue or disease specific. Multiple isoforms of ANRIL exist including 
both linear and circular forms with tissue-specific expression pat-
terns identified (41, 42). ANRIL isoforms with an ALU motif were 
found to be more effective in recruiting chromatin-remodeling 
proteins (21). The specific ANRIL isoforms increased in breast 
tumors were not identified so the tissue-specific differences 
between breast cancer and myocardium could be attributed to 
different ANRIL isoforms being present. The rs11515 SNP is 
predicted to affect the binding site of microRNA-601 (43), so the 
effect of rs11515 genotypes may be dependent of the expression 
of other transcripts.
Other 9p21 polymorphisms have been correlated with 
cancer including breast cancer (rs1011970), glioma (rs1063192, 
rs2157719, rs1412829, and rs4977756), basal cell carcinoma 
(rs2151280), nasopharyngeal carcinoma (rs1412829), and breast 
cancer (rs1011970 and rs3088440) [reviewed in Ref. (34, 44)]. 
Consequently, another polymorphism in linkage with rs11515 
could be the causal allele for the increased ANRIL expression. 
The rs3088440 polymorphism is located 40  bp downstream of 
rs11515. In a large cohort of over 3000 women with breast cancer, 
the rs3088440 minor allele was associated with breast cancer (34), 
and in pancreatic cancer associated with a reduced time to tumor 
progression and a poorer response to therapy (45). The rs3088440 
genotypes were not significantly increased in the breast cancer 
cohort in the current study; however, a limitation of the cur-
rent study was a smaller cohort was used (34). The majority of 
individuals’ heterozygote for the rs11515 allele were homozygote 
for the rs3088440 major allele; therefore, it is possible that a hap-
lotype contributes to the associations found in this study instead 
of the rs11515 genotype alone.
cOnclUsiOn
To our knowledge, this is the first report of an association between 
the rs11515 minor allele with breast cancer and a negative cor-
relation between ANRIL and p16INK4a levels with the CG genotype. 
Reduced expression of p16INK4a may be one mechanism by which 
the rs11515 CG genotype increases cancer risk.
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